On 3 April 2012, the UK's regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has published a draft Third Edition of its Blue Guide to the Advertising and Promotion of Medicines in the UK.

The new draft edition updates the guidance on the rules governing the advertisement of medicines in the UK in various ways.  However, what is likely to be most relevant to pharmaceutical companies are the updates in relation to:

  • the provision of information prior to the grant of a marketing authorisation; and
  • the use of digital communications.

The MHRA is inviting comments on the draft publication by 8 June 2012.  A finalised version is then due to be published in early July when the new Human Medicines Regulations come into force.